Hepatitis C, Chronic
Conditions
Brief summary
This randomized, open-label, multicenter study will evaluate the safety , efficacy and tolerability of the combination treatment RO5466731, RO5190591, ritonavir and Copegus (ribavirin) with or without RO5024048 in patients with chronic hepatitis C genotype 1. In Part 1, treatment-naïve patients will be randomized to receive treatment with RO5466731, RO5190591 plus ritonavir, and Copegus, with or without RO5024048. In Part 2, further treatment-naïve patients will receive a successful regimen from Part 1, or a reduced intensity regimen, and patients who have previously experienced null response to interferon-based treatment will be added to the study.
Interventions
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients, \>/= 18 years of age * Chronic hepatitis C genotype 1 of \>/= 6 months duration at screening * Part 1 and Part 2: Naïve to treatment with interferon (pegylated or non-pegylated). Patients who have participated in studies investigating a direct-acting antiviral agent with or without interferon are excluded * Part 2: Treatment experienced patients having a previous null response to treatment with interferon containing regimen * Liver biopsy or non-invasive (e.g. Fibroscan) evaluation in the past 24 calendar months showing absence of cirrhosis or incomplete/transition to cirrhosis * Body mass index (BMI) 18 to 35 kg/m2 inclusive and body weight \>/= 45 kg
Exclusion criteria
* Pregnant or lactating women or males with female partners who are pregnant or lactating * Decompensated liver disease or impaired liver function (as defined by protocol) * Cirrhosis or incomplete/transition to cirrhosis * Non- hepatitis C chronic liver disease * Positive for hepatitis B or HIV infection * History of pre-existing renal disease * History of severe cardiac disease * History of neoplastic disease within the last 5 years, except for localized or in situ carcinoma of the skin * History of drug abuse within the last year; history of cannabinoid use is not excluded * Evidence of alcohol abuse within 1 year of screening and consumption of more than 2 units of alcohol per day * Medical condition that requires use of systemic corticosteroids * Received warfarin or other anticoagulants during the 21 days immediately prior to screening or is expected to require warfarin or other anticoagulants during the study * Anticipated use or need for significant medical treatment during the study or use of concomitant medications or nutrients that are excluded by protocol (e.g. drugs that are contraindicated with ritonavir, hormonal methods of contraception)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained virological response (defined as undetectable serum HCV RNA) 12 weeks after end of treatment | approximately 20 months |
| Safety: Incidence of adverse events | approximately 20 months |
Secondary
| Measure | Time frame |
|---|---|
| Antiviral activity: Change in serum HCV RNA levels | from baseline to 24 weeks after end of treatment |
| Pharmacokinetics in coadministration: Area under the concentration-time curve (AUC) | Pre-dose Weeks 1, 2, 3, 4, 6, 10, and 12 and up to 12 hours post-dose Weeks 1, and 4 or 3 and 6 |
| HCV drug resistance | approximately 20 months |
| Quality of life: Short-Form 36v2/Brief Fatigue Inventory questionnaires | approximately 20 months |
Countries
Australia, Germany, New Zealand, Poland, United States
Outcome results
None listed